

Index

- 21 CFR 58, 166
 21 CFR 58.90, 165
 21 CFR 211.100, 166
 21 CFR 312.1, 167
 21 CFR 812, 167
 21 CFR 814, 220
 21 CFR 1270, 223
 66 FR 1507, 171
 63 FR 26744, 171
 63 FR 52696, 171
 21 U.S.C. 321(g), 169
 21 U.S.C. 353(g), 169
 21 U.S.C. 201(h), 169
 42 U.S.C. 262(a), 169
 42 U.S.C. 264, 171
- A**
- Acetabular reconstruction
 allografts with bipolar endoprosthesis, 81
 cancellous allograft, 78-80
 cementless cups, 77
 impaction grafting with cement, 80-81
 structural allografts, 71-72
- Acidic loading, polymers, 246
- Adeno-associated viral vectors, 150
- Adenoviruses, 150
- Allogeneic mesenchymal stem cells, 133, 135
- Allogenic products, with calcium sulfate, 267
- Allograft bone, 68-83
 advantages, 68
 basic science, 69
 fresh, 14, 69
 properties, 69
- Allograft musculoskeletal tissues, 30-52
 disease transmission, 44, 48-51
 distribution, 47-48
 donor screening, 38-39
 forms, 32
 governmental regulations, 35-37
 serological testing, 39-40
 sterility, 41-42
 tissue processing, 43-47
 tissue retrieval, 40-43
 tissue storage, 47
 trends of U. S. donors, 40-41
 usage, 30-31
- Allograft tissue banking, 36, 38
 history, 32-35
- Allograft transplant, history, 32-35
- Allografts, 5-6, 13-22
 disadvantages, 13
 disease transmission risk, 14
 freeze-dried, material properties, 14
 frozen, 14
 history, 3-4
 mineralized, 13-15
 sterility, 14-15
- ALLOMATRIX, 104-105
- American Association of Tissue Banks, 34
 standards, 115, 117
- Animals, use in preclinical studies, 165
- ASTM F 748, 299
 ASTM F 1581-99, 118
 ASTM F 1636, 303
 ASTM F 2064-00, 118
 ASTM F 2027-00e01, 118
 ASTM F 2103-01, 118
 ASTM F 2149-01, 118
 ASTM standards, 116, 299
- Athymic heterotropic implant rat model, 18
- Athymic rodent assay, 105-106
- Autocrine effect, 175
- Autogenous bone marrow, demineralized bone matrix enhancement, 20
- Autograft-based bone graft substitutes, 114
- Autografts
 complications of harvesting procedure, 5
 healing time comparison to bone graft substitutes, 290
 history, 3
 supply limitations, 5
- Autologous bone grafting, 1
- Autologous bone marrow, demineralized bone matrix, 21
- Autologous cell-matrix composite, 133, 135
- Autologous growth factor concentrate, 143
- B**
- Bending strength, irradiation effect, 45
- Best Practices for Organ and Tissue Donation, 59-61
- Bioactive glasses, 241-242
- Bioburden, 41-42
- Biocompatibility, standards, 298-300
- Biologic product, 169
- Biologic properties, irradiation

310 BONE GRAFT SUBSTITUTES

- effect, 46
 - Biological stimulants, 128-130
 - Bipolar endoprosthesis, 81
 - Boden animal model, 18
 - Bone banking, history, 4
 - Bone formation
 - new
 - biomechanical testing, 302
 - stages, 126-127
 - in vivo, difficulty in measuring, 291, 293-295
 - Bone fracture healing, cellular processes, 194-195
 - Bone graft procedures, number of, 4
 - Bone graft substitutes
 - allograft-based, 5-6
 - cell-based, 5-6
 - ceramic-based, 5-6
 - classification system, 5
 - current generation, 4
 - efficacy assessment, 290
 - evaluation, 113
 - factor-based, 5-6
 - healing time, comparison to autograft, 290
 - history, 4
 - ideal, 232
 - injectability, 295-296
 - malunion rate, 290-293
 - mechanical properties, 301
 - nonunion rate, 290
 - osteinduction, 295
 - polymer-based, 5, 7
 - prerequisites, 13
 - properties as carriers, 296
 - regulation, 214-225
 - general controls, 215-216
 - humanitarian device exemption, 221-222
 - pre-market approval, 220
 - pre-market notification, 217-219
 - product development protocol, 220-221
 - regulatory status, 222-224
 - structural properties, 295
 - U. S. sales, 30-31
 - Bone grafting, biology, 235-236
 - Bone healing, 234
 - Bone marrow
 - coralline porous ceramic graft substitutes, 279-280
 - efficacy and safety, 144-145
 - isolation, 131
 - Bone marrow-based grafts, 131
 - Bone morphogenetic protein implants, 194-208
 - historical perspective, 194-197
 - promises and challenges, 207-208
 - Bone morphogenetic proteins, 6, 129, 143, 180-183
 - accessibility to graft site, 97-104
 - bone forming activity, 196-197, 200-201, 203
 - bone morphogenetic potential, 197
 - carrier capable of extracting, 98
 - clinical study, 202, 204
 - delivery biomaterials, 199, 201-202
 - demineralized bone matrix and, 15, 207
 - effect on degradation of bone graft substitutes, 247
 - family, 197
 - in vivo bone remodeling effects, 204
 - purification, 196, 198
 - receptors, 204-206
 - regulatory status, 224
 - role in tissue morphogenesis, 206
 - structure, 196, 198-199
 - use, 181
 - Bone regeneration, 142
 - cellular events, 127
 - strategies for, 143
 - Bone substitutes
 - seeded with bone morphogenetic proteins, 30
 - U. S. sales, 30-31
 - Bone void fillers
 - calcium sulfate based products, 267
 - standards, 299
- C**
- Calcium phosphate
 - biphasic, 240-241
 - see also Hydroxyapatite
 - Calcium phosphates, 6
 - Calcium sulfate, 242-243
 - as bone graft substitute, 4
 - cements, 241
 - dissolution, 262-263
 - Calcium sulfate based bone void substitutes, 260-269
 - calcination, 262
 - chemical form, 260
 - clinical studies, 265-268
 - development, 260-264
 - hemihydrate, 262-263
 - preclinical studies, 264-266
 - products, 267

standards, 268
 tests for, 305
 Callus formation, 234-235
 Cancellous allograft, acetabular
 reconstruction
 cementless cups, 77
 rings/cages, 78-80
 Cancellous bone graft, total hip
 arthroplasty, 76-83
 Carriers, 154-155
 demineralized bone matrix, 244-245
 properties, 296
 synthetic bone graft substitutes
 as, 302
 Cavitary defects, packing,
 demineralized bone matrix, 20-
 21
 Cell based approach, 126-139
 choosing appropriate graft, 138
 future developments, 171
 Cellular systems, 142-156
 bone marrow, efficacy and safety,
 144-145
 carriers, 154-155
 cost, 155
 efficacy and safety, 144-147
 mesenchymal stem cells, efficacy
 and safety, 145-147
 see also Gene therapy
 Cementless component retention, 77-
 78
 Cementless cups, 77
 Center for Biologics Evaluation and
 Research, 169
 Ceramics, 5-6, 236
 Classification system
 bone graft substitutes, 5
 standards, 116
 Clinical Laboratory Improvement
 Amendments of 1988, 39
 Clinical study
 bone morphogenetic proteins, 202,
 204
 calcium sulfate based bone void
 substitutes, 265-268
 coralline porous ceramic graft
 substitutes, 281-284
 Current Good Manufacturing
 Practices, 166-169
 Good Laboratory Practices, 166
 initiation, 164-167
 investigational new drug
 application, 167
 performed overseas, 168
 preclinical studies, 164-166
 premarket submissions, 167-171
 recent regulatory developments,

170-171
 regulatory process, 169-170
 safety/feasibility study, 167-168
 Clinical trials
 choice of, 295-296
 goals, 289-290
 Consensus standards, 114-115
 Coralline porous ceramic graft
 substitutes, 237-240, 271-284
 animal studies, 277-281
 chemical properties, 276-277
 clinical studies, 281-284
 hydroxyapatite, 273-274
 manufacturing process, 273-275
 microstructures, 273
 osteoconduction, 277-279
 growth factors and 280-281
 osteogenesis and, 279-280
 physical properties, 275-276
 spinal fusion, 278-279, 283-284
 trauma models, 278
 Coralline process, origin, 272
 Cortical strut allografts, 73
 Cortico-cancellous bone autograft,
 130
 Cosmos, 32-33
 Culture-expanded cell technology,
 131-135
 Current Good Manufacturing
 Practices, 166-169

D

Damian, 32-33
 Degradation testing, 303
 Demineralization process, 16
 Demineralized bone matrix, 15-22,
 69, 76, 96-108, 128, 243-245
 ALLOMATRIX, 104-105
 augmentation of spinal fusion, 21-
 22
 autologous bone marrow, 21
 bone morphogenetic proteins and,
 15, 207
 carrier, 97-98, 106-107, 244-245
 clinical applications, 20-22
 currently available products, 101
 distribution, 47
 efficacy, effect of autogeneous
 bone marrow, 20
 formulation effect, 18-19
 graft orientation, 19
 Grafton family of products, 98-100
 human, 244
 mixed with cancellous bone chips,
 136
 new putties, 104, 106

312 BONE GRAFT SUBSTITUTES

optimal properties, 98-99
OSTEOFIL, 101-103
osteointductivity, 15, 104-107
 as variability between batches, 19-20
particulates, 128
regulatory status, 223-224
safety profile, 17-18
toxicity potential, 17
variation in processing and sterilization, 15-17
viability, 19-20
 see also Grafton Gel
Demineralized freeze-dried bone allograft, 243
Deproteinized bone, 240
Disease transmission, 44, 48-51
 allografts, 14, 17
 demineralized bone matrix, 17
Distribution of tissues, 47-48
Donor screening, 14, 35, 38-39
 period between infection and detection, 40
Donor-site morbidity, 5, 70, 130
DynaGraft, 100-102

E

Efficacy
 assessment, 290
 problems with testing, 291
 standards, 300-304
Ethanol, effect on demineralized bone matrix, 16
Ethical controversy, 115
Ethylene oxide, 43-44
 effect on demineralized bone matrix, 16
Extracellular matrix, 126

F

Femor
 impaction allografting with cement, 82-83
 lesional treatment of osteolysis with cancellous grafting, 81-82
 reconstruction, total hip arthroplasty, 73-76
Femoral defects, healing using BMP-2-producing bone marrow cells, 151-154
Fibroblast growth factor, 6, 183-185
Final Rule on Human Tissue Intended for Transplantation, 35
Food and Drug Administration, office

 of combination products, 115
Food, Drug, and Cosmetic Act, 167, 215, 220, 222, 224
Fracture healing, growth factor role, 235
Freeze-drying, allografts, 14

G

Gene therapy, 147-154
 adenoviruses, 150
 bone morphogenetic proteins, 182
 ex vivo, autologous MSCs, 153
 fundamental elements, 148
 in vivo and ex vivo strategies, 150-151
 process of delivery to target cells, 148-149
 retroviral vectors, 149-150
 transduction, 148-149
Glasses, bioactive, 241-242
Good Clinical Practice, 168
Good Laboratory Practices, 166
Good tissue practice, 43, 52
Grafton flex, formulations, 18-19
Grafton Gel, 96, 98-100
Grafton Putty, 99-100
 dose-dependent toxicity, 17-18
 formulations, 18-19
Growth and differentiation factors, 180
Growth factor based systems, 174-187
 bone morphogenetic proteins, 180-183
 fibroblast growth factor, 183-185
 insulin-like growth factor, 186-187
 platelet-derived growth factor, 6, 129, 185-186
 transformation growth factor- β , 6, 129, 176-180
Growth factors, 143, 271
 autologous concentrate, 143
 functions, 280-281
 release during bone healing, 175
 role in fracture healing, 235
Guidance for Industry: Fast Track Development Program, 168
Gypsum, 262

H

Harvesting procedure, complications, 5
Hemihydrate, 262-263
Hepatitis C, 35
 transmission, non-irradiated bone

allografts, 49-50

HIV
 radiosensitivity, 44
 transmission, 14, 50-51

Human cells, tissue, and cellular
 and tissue-based products
 recent regulatory developments,
 170
 regulation, 114-115

Human Cells, Tissues, and Cellular &
 Tissue Based Products;
 Establishment Registration
 and Listing, 36

Humanitarian device exemption, bone
 graft substitutes, 221-222

Hyatt, George, 34

Hydroxyapatite, 236-241
 biphasic calcium phosphate, 240-
 241
 calcium phosphate cements, 241
 deproteinized bone, 240
 mechanical properties, 275
 pore size and porosity, 237
 tricalcium phosphates, 240
 see also Coralline bone graft
 substitutes

I

Iliac crest autograft, disadvantages
 and limitations, 130

Imhotep, 3

Impaction allografting, 69
 acetabular, with cement, 80-81
 complications, 83
 with cement, femur, 82-83

Institutional Animal Care and Use
 Committee, 165

Insulin-like growth factor, 186-187

Interim Rule on Human Tissue
 Intended for Transplantation,
 34-35

International Standards
 Organization, 118

Investigational new drug
 application, 167

Irradiation, effects, 43-46
 on soft tissue, 46-47

ISO 10993, 299

J

Joint Accreditation for
 Accreditation of HealthCare
 Organization, 35-36

Joint replacement, structural
 allografts, 71-72

L

LIM mineralization protein-1, 152

Lymphophilization, 14, 69

M

Malunion rate, bone graft
 substitutes, 290-293

Market approval, pathways for, 114

Material properties, freeze-dried
 allograft, 14

Mechanical testing, 300

Medical device
 classification, 215, 217
 definition, 215

Medical Device Amendments of 1976,
 220, 222

Medicine, history, 3

Mesenchymal stem cells, 126-127
 autologous, ex vivo gene therapy,
 153
 in bone healing, 234
 clinical implementation of
 therapy, 146-147
 culture expanded human, 132-133
 culturing, 131
 differentiation, 146
 efficacy and safety, 145-147
 loaded implants, 132-133

Mineralized allografts, 13-15

Morbidity and Mortality Report, 48-
 49

N

National Organ Transplant Act, 35

Non-union treatments
 demineralized bone matrix and
 autologous bone marrow, 21
 history, 3

Nonunion rate, bone graft
 substitutes, 290

Nucleic acid amplification test, 39-
 40

O

OECD guidelines, 299

OP-1 Implant, 224

Organ procurement organization, 36

Osteoarticular allografts, 70

Osteoblasts, predifferentiated, 132

Osteochondral allografts, 14

Osteochondroprogenitor cells, 234

Osteoconductive grafts, 128, 138-139

314 BONE GRAFT SUBSTITUTES

Osteoconductivity, 4, 232-233, 271-272
 coralline porous ceramic graft substitutes, 277-279
 demineralized bone matrix, 16
OSTEOFIL, 101-103
Osteogenesis, 232, 271
 coralline porous ceramic graft substitutes, 279-280
Osteogenetic protein, 174, 181-182
Osteogenic grafts, 130-136
 use, 138-139
Osteogenicity, 4
Osteoinductive grafts, 128, 138-139
Osteoinductivity, 4, 76, 232
 assessment methods, 105-107
 athymic heterotropic implant rat model, 18
 bone graft substitutes, 295
 demineralized bone matrix, 15, 104-107, 243
 variability between batches, 19-20
 ethylene oxide effect, 16
 freeze-drying effects, 14
Osteolysis, 78
 lesional treatment, 81-82
Osteolytic defects, grafting, 77-78
Osteopromotive grafts, 129, 138-139

P

Paracrine effect, 175
Percutaneous injectable delivery, 295-296
Plaster of Paris, 262
Platelet-derived growth factor, 6, 129, 185-186
Platelet rich plasma, 129-130
Poloxamer 407, 100-101
Polyhydroxy acid family, 246
Polymer-based groups, 7
Polymers, 245-248
 acidic loading, 246
 pore sizes, 247
Preclinical studies, calcium sulfate based bone void substitutes, 264-266
Predicate device, 217-219
Pre-market approval, 220
Pre-market Approval Application, 222
Pre-market notification, 217-219
Premarket submissions, 167-171
Prion-related diseases, 17
Pro Osteon, 273-274, 276
Product development protocol, bone

 graft substitutes, 220-221
Proposed Approach to Regulation of Cellular and Tissue-Based Products, 36
Proposed Approach to the Regulation of Cellular- and Tissue-based Products, 223-224
Proposed Rule for Donor Suitability Determination for Tissue Donation, 36
Proposed Rule for Good Tissue Practices, 36
Proprietary sterilization techniques, 44
Public Health Service Act, 171

R

Radiolucencies, 77-78
Regulatory process, clinical study, 169-170
Regulatory status, 222-224
 bone morphogenetic proteins, 224
 demineralized bone matrix, 223-224
Resorbable Calcium Salt Bone Void Filler Device; Draft Guidance for Industry and FDA, 299
Retroviral vectors, 149-150

S

 Safe Medical Devices Act of 1990, 169, 221
Safety, standards, 298-300
Screw pull out, 45
Selective cell retention technology, 135-136
Serological testing, 39-40
SMADS, 177-178
Soft tissue allografts, irradiation effect, 46-47
Specification, standards, 116-117
Spinal fusion
 augmentation with demineralized bone matrix, 21-22
 BMP-2 studies, 181
 calcium sulfate based bone void substitutes, 264-265
 coralline porous ceramic graft substitutes, 283-284
 models, coralline porous ceramic graft substitutes, 278-279
Spine, structural allografts, 70-71
Standards, 113-118
 American Association of Tissue Banks, 115, 117
 application to clinical practice,

304-305
 ASTM, 116, 299
 calcium sulfate based bone void
 substitutes, 268
 classification, 116
 consensus, 114-115
 efficacy and performance, 300-304
 International Standards
 Organization, 118
 safety and biocompatibility, 298-
 300
 specification, 116-117
 Tissue Engineered Medical
 Products, 117-118
 Sterility, allografts, 14-15
 Structural allografts, 70-72
 Structural grafts, 69
 Substantial equivalent decision-
 making process, 218-219
 Synthetic bone graft substitutes,
 235-248
 bioactive glasses, 241-242
 calcium sulphate, 242-243
 ceramics, 236
 demineralized bone graft, 243-245
 efficacy and performance, 201
 hydroxyapatite, 236-241
 polymers, 245-248
 regulatory status, 222-223
 as scaffolds or carriers, 302

T

Test method standards, 117
 Tissue, contamination, 42-43
 Tissue banking, 36, 38
 history, allografts, 32-35
 Tissue-Engineered Medical Products,
 299
 standards, 117-118
 Tissue engineering, 143
 biology, 207
 bone morphogenetic proteins, 206-
 207
 Tissue processing, 43-47
 Tissue reference group, 114
 Tissue retrieval, 40-43
 Tissue storage, 47
 Total hip arthroplasty
 cancellous bone graft, 76-83
 femoral reconstruction, 73-76
 Total knee arthroplasty, revision, 7
 3-76
 Toxicity studies, in animals, 165
 Transduction, 148-149, 151-152
 Transformation growth factor- β , 6,

129, 176-180
 effects, 178
 isoforms, 179
 recent studies, 179-180
 receptors, 177
 Trauma models, coralline porous
 ceramic graft substitutes, 278
 Triad of Osteoconduction, 272, 279
 Triad of Tissue Regeneration, 271-
 272
 Tricalcium phosphates, 240
 Tuberculosis, associated with tissue
 implantation, 48
 Tumor reconstruction, 70

U

Uniform Anatomical Gift Act, 35-36

V

Vascular endothelial growth factor,
 129

W

Wound healing, biology, 233-234
 Wright Plaster of Paris Pellets, 223